Literature DB >> 30389589

Gastrointestinal Infection Increases Odds of Inflammatory Bowel Disease in a Nationwide Case-Control Study.

Jordan E Axelrad1, Ola Olén2, Johan Askling3, Benjamin Lebwohl4, Hamed Khalili5, Michael C Sachs3, Jonas F Ludvigsson6.   

Abstract

BACKGROUND & AIMS: Gastrointestinal infections have been associated with later development of inflammatory bowel diseases (IBD). However, studies have produced conflicting results. We performed a nationwide case-control study in Sweden to determine whether gastroenteritis is associated with the development of Crohn's disease (CD) or ulcerative colitis (UC).
METHODS: Using the Swedish National Patient Register, we identified 44,214 patients with IBD (26,450 with UC; 13,387 with CD; and 4377 with IBD-unclassified) from 2002 to 2014 and matched them with 436,507 individuals in the general population (control subjects). We then identified patients and control subjects with reported episodes of gastroenteritis (from 1964 to 2014) and type of pathogen associated. We collected medical and demographic data and used logistic regression to estimate odds ratios (ORs) for IBD associated with enteric infection.
RESULTS: Of the patients with IBD, 3105 (7.0%) (1672 with UC, 1050 with CD, and 383 with IBD-unclassified) had a record of previous gastroenteritis compared with 17,685 control subjects (4.1%). IBD cases had higher odds for an antecedent episode of gastrointestinal infection (aOR, 1.64; 1.57-1.71), bacterial gastrointestinal infection (aOR, 2.02; 1.82-2.24), parasitic gastrointestinal infection (aOR, 1.55; 1.03-2.33), and viral gastrointestinal infection (aOR, 1.55; 1.34-1.79). Patients with UC had higher odds of previous infection with Salmonella, Escherichia coli, Campylobacter, or Clostridium difficile compared to control subjects. Patients with CD had higher odds of previous infection with Salmonella, Campylobacter, Yersinia enterocolitica, C difficile, amoeba, or norovirus compared to control subjects. Increasing numbers of gastroenteritis episodes were associated with increased odds of IBD, and a previous episode of gastroenteritis remained associated with odds for IBD more than 10 years later (aOR, 1.26; 1.19-1.33).
CONCLUSIONS: In an analysis of the Swedish National Patient Register, we found previous episodes of gastroenteritis to increase odds of later development of IBD. Although we cannot formally exclude misclassification bias, enteric infections might induce microbial dysbiosis that contributes to the development of IBD in susceptible individuals.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epidemiology; Immune Response; Microbiome; Risk Factor

Year:  2018        PMID: 30389589     DOI: 10.1016/j.cgh.2018.09.034

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  14 in total

1.  Campylobacter jejuni persistently colonizes gnotobiotic altered Schaedler flora C3H/HeN mice and induces mild colitis.

Authors:  Meghan Wymore Brand; Orhan Sahin; Jesse M Hostetter; Julian Trachsel; Qijing Zhang; Michael J Wannemuehler
Journal:  FEMS Microbiol Lett       Date:  2020-11-05       Impact factor: 2.742

2.  Systematic review: gastrointestinal infection and incident inflammatory bowel disease.

Authors:  Jordan E Axelrad; Ken H Cadwell; Jean-Frederic Colombel; Shailja C Shah
Journal:  Aliment Pharmacol Ther       Date:  2020-05-05       Impact factor: 8.171

3.  Prevalence of coexisting autoimmune thyroidal diseases in coeliac disease is decreasing.

Authors:  Patricia Dominguez Castro; Grace Harkin; Mary Hussey; Brian Christopher; Clifford Kiat; Jun Liong Chin; Valerie Trimble; Deirdre McNamara; Padraic MacMathuna; Brian Egan; Barbara Ryan; David Kevans; Mohamed Abuzakouk; Richard Farrell; Con Feighery; Valerie Byrnes; Nasir Mahmud; Ross McManus
Journal:  United European Gastroenterol J       Date:  2020-01-07       Impact factor: 4.623

4.  Gastrointestinal Infection and Risk of Microscopic Colitis: A Nationwide Case-Control Study in Sweden.

Authors:  Hamed Khalili; Jordan E Axelrad; Bjorn Roelstraete; Ola Olén; Mauro D'Amato; Jonas F Ludvigsson
Journal:  Gastroenterology       Date:  2021-01-06       Impact factor: 22.682

Review 5.  Effects of Intestinal Fungi and Viruses on Immune Responses and Inflammatory Bowel Diseases.

Authors:  Iliyan D Iliev; Ken Cadwell
Journal:  Gastroenterology       Date:  2020-12-19       Impact factor: 22.682

6.  Enteric viruses evoke broad host immune responses resembling those elicited by the bacterial microbiome.

Authors:  Simone Dallari; Thomas Heaney; Adriana Rosas-Villegas; Jessica A Neil; Serre-Yu Wong; Judy J Brown; Kelly Urbanek; Christin Herrmann; Daniel P Depledge; Terence S Dermody; Ken Cadwell
Journal:  Cell Host Microbe       Date:  2021-04-23       Impact factor: 31.316

Review 7.  Salmonella Infection in Chronic Inflammation and Gastrointestinal Cancer.

Authors:  Lang Zha; Shari Garrett; Jun Sun
Journal:  Diseases       Date:  2019-03-10

8.  Rapid expansion of Treg cells protects from collateral colitis following a viral trigger.

Authors:  Michelle Schorer; Katharina Lambert; Nikolas Rakebrandt; Felix Rost; Kung-Chi Kao; Alexander Yermanos; Roman Spörri; Josua Oderbolz; Miro E Raeber; Christian W Keller; Jan D Lünemann; Gerhard Rogler; Onur Boyman; Annette Oxenius; Nicole Joller
Journal:  Nat Commun       Date:  2020-03-23       Impact factor: 14.919

9.  Early life exposures and the risk of inflammatory bowel disease: Systematic review and meta-analyses.

Authors:  Manasi Agrawal; João Sabino; Catarina Frias-Gomes; Christen M Hillenbrand; Celine Soudant; Jordan E Axelrad; Shailja C Shah; Francisco Ribeiro-Mourão; Thomas Lambin; Inga Peter; Jean-Frederic Colombel; Neeraj Narula; Joana Torres
Journal:  EClinicalMedicine       Date:  2021-05-15

10.  Nonclostridium difficile enteric infection and the risk of developing inflammatory bowel disease: A systematic review and meta-analysis.

Authors:  Cong Dai; Yu-Hong Huang; Min Jiang; Ming-Jun Sun
Journal:  Saudi J Gastroenterol       Date:  2020-10-28       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.